Abstract
The gastrointestinal tract is the most common extranodal site of non-Hodgkin lymphoma. The gastrointestinal lymphoma represents a heterogeneous disease, where diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue (MALT) lymphoma are the most common subtypes. The role of radiotherapy varies in the treatment of lymphomas from different sites or with different subtypes. Conservative treatment using chemotherapy and/or radiotherapy produced favorable outcomes in gastric lymphoma. In gastric DLBCL, radiotherapy after chemotherapy improved locoregional control and survival, even for patients who achieved complete response after chemotherapy. In the era of rituximab, radiotherapy also improved locoregional control in patients with bulky disease. In gastric MALT lymphoma, radiotherapy alone could yield excellent outcomes for patients who are unresponsive to H. pylori eradication. However, surgery remains the mainstay of radical treatment for intestinal lymphoma, and radiotherapy is also a choice for indolent subtypes. Key words: Gastrointestinal tract; Lymphoma, non-Hodgkin; Diffuse large B cell lymphoma; Mucosa-associated lymphoid tissue
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
